X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

EFTRW

Closed

Effector Therapeutics Inc

0.0006
0.0000 (0.00%)
Last Update: 16 Oct 2024 18:18:00
Yesterday: 0.0006
Day's Range: 0.0006 - 0.0006
Send
When Written:
 
0.1292
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company that is focused on developing selective translation regulators (STRs) for the treatment of cancer. The company's proprietary platform technology allows for the identification of STRs that selectively inhibit the translation of specific mRNAs, which are frequently overexpressed in cancer cells.

eFFECTOR has several product candidates in its pipeline, including eFT508, which is being developed for the treatment of solid tumors and lymphoma. The company is also developing eFT226, which is designed to target KRAS mutations in cancer, and eFT719, which is being developed for the treatment of hematologic malignancies.

eFFECTOR was founded in 2012 and is headquartered in San Diego, California. The company has partnerships with several pharmaceutical companies, including Pfizer and Astellas Pharma, to develop and commercialize its product candidates.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X